Phospho-CD79A (Tyr210) (E8E9Z) Rabbit mAb (Alexa Fluor® 488 Conjugate) #15968
- F
Supporting Data
REACTIVITY | H |
SENSITIVITY | Endogenous |
MW (kDa) | |
Source/Isotype | Rabbit IgG |
Application Key:
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Description
Product Usage Information
Application | Dilution |
---|---|
Flow Cytometry (Fixed/Permeabilized) | 1:50 |
Storage
Protocol
Specificity / Sensitivity
Phospho-CD79A (Tyr210) (E8E9Z) Rabbit mAb (Alexa Fluor® 488 Conjugate) recognizes endogenous levels of CD79A protein only when phosphorylated at Tyr210.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr210 of human CD79A protein.
Background
Antigen receptors found on the surface of B cells contain a heterodimeric signaling component composed of CD79A and CD79B, also known as Ig α and Ig β, respectively (1,2). Presence of this receptor complex is essential for B cell development and function (3). Together these two proteins and the associated B cell receptor (BCR) initiate intracellular signaling following antigen binding (4,5). An immunoreceptor tyrosine-based activation motif (ITAM) found in the CD79A intracellular region appears to be important for its function (6). Antigen binding precedes formation of the CD79A and CD79B heterodimer and subsequent activation of receptor associated kinases (7). Research has shown that CD79A is a marker for B-lineage lymphoblastic leukemia (8). Additionally, investigators have found that mutations in the CD79A (MB1) gene are associated with abnormally low levels of functional B cell receptors in some cases of chronic B cell lymphocytic leukemia (9).
Tyrosine 210 is an evolutionarily conserved non-ITAM tyrosine residue that lies within the cytoplasmic domain of CD79A/Ig-α. Research studies have shown that ligation of the BCR induces phosphorylation of tyrosine 210, which facilitates both the recruitment of BLNK to the BCR signaling complex and the activation of downstream Syk-dependent signaling (10,11). Collectively, these molecular events drive B cell activation and proliferation (12).
- van Noesel, C.J. et al. (1991) J Immunol 146, 3881-8.
- Minegishi, Y. et al. (1999) J Clin Invest 104, 1115-21.
- Yu, L.M. and Chang, T.W. (1992) J Immunol 148, 633-7.
- Storch, B. et al. (2007) Eur J Immunol 37, 252-60.
- Mason, D.Y. et al. (1995) Blood 86, 1453-9.
- Luisiri, P. et al. (1996) J Biol Chem 271, 5158-63.
- Pike, K.A. et al. (2004) J Immunol 172, 2210-8.
- Astsaturov, I.A. et al. (1996) Leukemia 10, 769-73.
- Vuillier, F. et al. (2005) Blood 105, 2933-40.
- Engels, N. et al. (2001) Eur J Immunol 31, 2126-34.
- Kabak, S. et al. (2002) Mol Cell Biol 22, 2524-35.
- Patterson, H.C. et al. (2006) Immunity 25, 55-65.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.